ipragliflozin + Metformin + Placebo
Phase 2Completed 0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2
Trial Timeline
Mar 3, 2010 → Apr 11, 2011
NCT ID
NCT01071850About ipragliflozin + Metformin + Placebo
ipragliflozin + Metformin + Placebo is a phase 2 stage product being developed by Astellas Pharma for Diabetes Mellitus, Type 2. The current trial status is completed. This product is registered under clinical trial identifier NCT01071850. Target conditions include Diabetes Mellitus, Type 2.
What happened to similar drugs?
20 of 20 similar drugs in Diabetes Mellitus, Type 2 were approved
Approved (20) Terminated (0) Active (0)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01071850 | Phase 2 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2